Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity

Gene Therapy

Volumn 22, Issue 7, 2015, Pages 596-601

  Rodriguez Garcia A ^a   Svensson, E ^b   Gil Hoyos, R ^a   Fajardo, C A ^a   Rojas, L A ^a   Arias Badia, M ^a   Loskog, A S I ^a   Alemany, R ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BREFELDIN A; E3 19K PROTEIN; EPITOPE; FURIN; GAMMA INTERFERON; GLYCOPROTEIN GP 100; LACTACYSTIN; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG; VIRUS PROTEIN; ABC TRANSPORTER; E3 GLYCOPROTEIN 19K, ADENOVIRUS TYPE 7; ONCOLYTIC VIRUS; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING (TAP);

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL; CONTROLLED STUDY; DENDRITIC CELL; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MASTOCYTOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSPORTER ASSOCIATED TO ANTIGEN PROCESSING; TUMOR ESCAPE; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN ADENOVIRUS C; METABOLISM; NEOPLASMS; TUMOR CELL LINE;

ADENOVIRIDAE;

ADENOVIRUS E3 PROTEINS; ADENOVIRUSES, HUMAN; ANIMALS; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; EPITOPES; FEMALE; HEK293 CELLS; HUMANS; MICE, INBRED C57BL; MUTAGENESIS, INSERTIONAL; NEOPLASMS; ONCOLYTIC VIRUSES;

EID: 84934439518     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.41     Document Type: Article

References (25)

1. Alemany R, Cascallo M. Oncolytic viruses from the perspective of the immune system. Future Microbiol 2009; 4: 527-536.
2. Woller N, Gurlevik E, Ureche CI, Schumacher A, Kuhnel F. Oncolytic viruses as anticancer vaccines. Front Oncol 2014; 4: 188.
3. Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y et al. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 2013; 12: 103.
4. Rodriguez-Rocha H, Gomez-Gutierrez JG, Garcia-Garcia A, Rao XM, Chen L, McMasters KM et al. Adenoviruses induce autophagy to promote virus replication and oncolysis. Virology 2011; 416: 9-15.
5. Jiang H, White EJ, Rios-Vicil CI, Xu J, Gomez-Manzano C, Fueyo J. Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J Virol 2011; 85: 4720-4729.
6. Schirmbeck R, Reimann J, Kochanek S, Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vectorencoded transgenic antigens. Mol Ther 2008; 16: 1609-1616.
7. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2012; 122: 359-367.
8. Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst 2013; 105: 1172-1187.
9. Lu J, Higashimoto Y, Appella E, Celis E. Multiepitope trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol 2004; 172: 4575-4582.
10. Raafat N, Sadowski-Cron C, Mengus C, Heberer M, Spagnoli GC, Zajac P. Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope. Int J Cancer 2012; 131: E659-E669.
11. Gil-Torregrosa BC, Castano AR, Lopez D, Del Val M. Generation of MHC class I peptide antigens by protein processing in the secretory route by furin. Traffic 2000; 1: 641-651.
12. Maecker HT, Umetsu DT, DeKruyff RH, Levy S. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. J Immunol 1998; 161: 6532-6536.
13. Werlen G, Hausmann B, Palmer E. A motif in the alphabeta T-cell receptor controls positive selection by modulating ERK activity. Nature 2000; 406: 422-426.
14. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K et al. gp100/ pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998; 188: 277-286.
15. Rojas JJ, Gimenez-Alejandre M, Gil-Hoyos R, Cascallo M, Alemany R. Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD. Gene Ther 2011; 19: 453-457.
16. Rojas JJ, Guedan S, Searle PF, Martinez-Quintanilla J, Gil-Hoyos R, Alcayaga-Miranda F et al. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Mol Ther 2010; 18: 1960-1971.
17. Bayo-Puxan N, Gimenez-Alejandre M, Lavilla-Alonso S, Gros A, Cascallo M, Hemminki A et al. Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. Hum Gene Ther 2009; 20: 1214-1221.
18. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997; 6: 715-726.
19. Agrawal S, Reemtsma K, Bagiella E, Oluwole SF, Braunstein NS. Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma. Cell Immunol 2004; 228: 130-137.
20. Seliger B, Wollscheid U, Momburg F, Blankenstein T, Huber C. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res 2001; 61: 1095-1099.
21. Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M et al. IFNgamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine 2010; 28: 3548-3557.
22. Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004; 27: 184-190.
23. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54: 777-785.
24. Winzler C, Rovere P, Rescigno M, Granucci F, Penna G, Adorini L et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997; 185: 317-328.
25. Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GW. Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques 2008; 45: 659-662; 64-68.